¿¬±¸°³¹ßÇ°¸ñ

R&D Product

¾È±¹¾àÇ°ÀÇ ±â¼ú·Î »î¿¡´Â °Ç°­À»
¹Ì·¡¿¡ Èñ¸ÁÀ» ÀüÇÏ°Ú½À´Ï´Ù.

¿¬±¸°³¹ßÇ°¸ñ.

R&D PRODUCT

·¹º¸»ìźÁ¤

°³¿ä
1. ±¹³» ÃÖÃÊ S-Amlodipine besylate¿Í ValsartanÀÇ º¹ÇÕÁ¦ÀÔ´Ï´Ù.
2. ¿ì¼öÇÑ Ç÷¾Ð °­ÇÏ È¿°ú¿Í ÇÔ²² »óÈ£ º¸¿Ï ÀÛ¿ë¿¡ ÀÇÇÑ ºÎÀÛ¿ë °¨¼Ò°¡ Ư¡ÀÔ´Ï´Ù.
3. ¹°¸®È­ÇÐÀûÀ¸·Î ¶Ù¾î³­ ¾ÈÁ¤¼º - Èí½À¼ºÀÌ ¾ø¾î º°µµÀÇ ¾Ë·ç¹Ì´½ Æ÷ÀåÀÌ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.
ÀûÀÀÁõ
°íÇ÷¾Ð

·¹ÅäÇÁ¶óÁ¤ (±¹³» ÃÖÃÊ ¼ø¼öÇÑ S-ÆÇÅäÇÁ¶óÁ¹ Á¦Á¦)

°³¿ä
1. ·¹ÅäÇÁ¶ó´Â Pantoprazole Á¦Á¦¿Í »ý¹°ÇÐÀû µ¿µî¼ºÀÌ ÀÔÁõµÈ S-Pantoprazole Á¦Á¦ÀÔ´Ï´Ù.
2. ·¹ÅäÇÁ¶ó´Â Pantoprazole Á¦Á¦ÀÇ Àý¹Ý ¿ë·®À¸·Î µ¿µîÇÑ È¿°ú¸¦ ³ªÅ¸³À´Ï´Ù.
ÀûÀÀÁõ
¼ÒÈ­¼º±Ë¾ç¿ëÁ¦

·¹º¸¸ð½ºÁ¤

°³¿ä
1. ±¹³» ÃÖÃÊ S-Amlodipine besylate¿Í OlmesartanÀÇ º¹ÇÕÁ¦ÀÔ´Ï´Ù.
2. ·¹º¸¸ð½ºÀÇ OlmesartanÀº À¯ÀÇÇÑ 24h Ambulatory BP °­ÇÏ È¿°ú¸¦ º¸¿´½À´Ï´Ù.
3. ·¹º¸¸ð½º´Â ÇÏ·ç ÇÑ ¹ø º¹¿ëÀ¸·Î, ÇÏ·ç µ¿¾È Ç÷¾ÐÀ» Áö¼ÓÀûÀ¸·Î °¨¼Ò½Ãų ¼ö ÀÖ´Â CCB+ARB º¹ÇÕÁ¦ÀÔ´Ï´Ù.
ÀûÀÀÁõ
°íÇ÷¾Ð

·¹º¸ÅÙ¼ÇÁ¤ (±¹³» ÃÖÃÊ ¼ø¼öÇÑ S-Amlodipine Á¦Á¦)

°³¿ä
1. ±âÁ¸ÀÇ RS-AmlodipineÀº À̼ºÀýüÀÎ S-Amlodipine°ú R-AmlodipineÀÌ 50:50ÀÇ ºñÀ²·Î È¥ÇÕµÈ È­ÇÕ¹°ÀÔ´Ï´Ù.
2. S-AmlodipineÀº Ç÷¾Ð°­ÇÏÀÛ¿ëÀ» È°¼ºÈ­½ÃÅ°´Â À¯È¿¼ººÐÀ̸ç R-Amlodipineº¸´Ù Ä®½·Ã¤³ÎÂ÷´Ü ÀÛ¿ëÀÌ 1000¹è ÀÌ»ó °­ÇÕ´Ï´Ù.
3.·¹º¸ÅÙ¼ÇÀº À¯È£¼ººÐÀÎ S-AmlodipineÀ» ÀÌ¿ëÇÏ¿© ¼±ÅÃÀû Ä®½·Ã¤³ÎÂ÷´ÜÀ» ÇÕ´Ï´Ù.
ÀûÀÀÁõ
1. °íÇ÷¾Ð
2. °ü»óµ¿¸ÆÀÇ °íÁ¤Æó¼â
3. °ü»óÇ÷°ü°èÀÇ Ç÷°ü°æ·Ã°ú Ç÷°ü ¼öÃà¿¡ ÀÇÇÑ ½É±Ù¼º ÇãÇ÷Áõ
°ü·Ã³í¹®
1. J, Pharm Pharmaceut Sci, 2001;185-200.
2. JMA-India, 2004;3(11)71-14.
3. Chirality, 1993;5(1):15-19.
4. J, Cardiovasc, Pharmacol, 19995-25;25(2):268-272.
5. JAMA-india, 2004;3(1)71-75.
6. Chirality, 1989;1(3):209-215.
7. J, Clin, Bas, Cardiol, 1998;1:14-18.
8. Br, J, Pharmacol, 1988;95:55-66.
¼ö»ó±â·Ï
1. Á¦ 8ȸ ´ëÇѹα¹ »óÇ°´ë»ó ±â¼úÇõ½ÅºÎ¹® ´ë»ó ¼ö»ó(2008³â 5¿ù 31ÀÏ)

·¹º¸Å׳îÁ¤ (±¹³» ÃÖÃÊ ¼ø¼öÇÑ S-Atenolol Á¦Á¦)

°³¿ä
1. ·¹º¸Å׳îÀº Atenolol Á¦Á¦¿Í »ý¹°ÇÐÀû µ¿µî¼ºÀÌ ÀÖ´Â S-Atenolol Á¦Á¦ÀÔ´Ï´Ù.
2. ·¹º¸Å׳îÀº °íÇ÷¾Ð ȯÀÚ¿¡ ´ëÇÑ Atenolol Á¦Á¦¿Í ºñ±³ÀÓ»ó½ÃÇè¿¡¼­ µ¿µî ÀÌ»óÀÇ Ç÷¾Ð °­ÇÏÈ¿°ú°¡ ÀÔÁõµÇ¾ú½À´Ï´Ù.
3. ·¹º¸Å׳îÀº Atenolol Á¦Á¦ÀÇ Àý¹Ý ¿ë·®À¸·Îµµ µ¿µîÀÌ»óÀÇ Ç÷¾Ð °­ÇÏÈ¿°ú¸¦ ³ªÅ¸³Â½À´Ï´Ù.
ÀûÀÀÁõ
1. °íÇ÷¾Ð
2. Çù½ÉÁõ

¾Ö´ÏÄÚÇÁ

°³¿ä
1.Cocoa ¶Ç´Â chocolate ¿¡¼­ ÃßÃâÇÑ ¹°ÁúÀÇ ½Å°³³ä ÁøÇØÁ¦. ÄÚµ¥Àκ¸´Ù ºñ¿­µîÀûÀÎ ÁøÇØÈ¿°ú
ÀûÀÀÁõ
1. ºñ¿°, ºñÀÎÈÄ¿°, ºÎºñµ¿¿°¿¡ ÀÇÇÑ Èĺñ·ç, ¸¸¼º±â°üÁö¿°¿¡ ÀÇÇÑ ±âħÀÇ ¿ÏÇÏ
°ü·Ã³í¹®
1. The antitussive effect of theobromine, caffeine and reference codeine, on 15% citric acid spray Induced cough model in guinea pig after oral administration (1997)
2. The time dependency of the antitussive effect of theobromine on 15% citric acid spray induced cough Model in guinea pig after oral administration (1997)
3. Testing the antitussive effect of theonromine during chronic treatment on 15% citric acid spray evoked cough model in guinea-pig (1997)
4. The effect of theobromine on the mucociliary clearance activity in rabbits airways(1997)

¼¼´ÙÅç SRÁ¤ (°ú¹Î¼º ¹æ±¤Ä¡·áÀÇ ´ºÆз¯´ÙÀÓ)

°³¿ä
1. ¼¼´ÙÅç SRÁ¤Àº ĸ½¶ÀÇ ºÒÆíÇÔÀ» Á¤Á¦·Î °³¼±ÇÏ°í º¹¿ëȽ¼ö¿Í Å©±â¸¦ ÁÙÀÎ Â÷¼¼´ë Tolterodine Á¦Á¦ÀÔ´Ï´Ù.
ÀûÀÀÁõ
1. Àý¹Ú´¢, ºó´¢ ¶Ç´Â Àû¹æ¼º ¿ä½Ç±Ý°ú °°Àº Áõ»óÀÇ °úÈ°µ¿¼º ¹æ±¤ Ä¡·á
°ü·ÃƯÇã
1. Á¶¼º¹° ƯÇãÃâ¿ø(10-2006-007059)

¾Ö´ÏÆæ (100% È°¼ºÇü ¼Ò¿° ÁøÅëÁ¦)

°³¿ä
1.¾Ö´ÏÆæÁ¤Àº À̺ÎÇÁ·ÎÆæ°ú ºñ±³ÇÏ¿© Â÷º°È­µÇ´Â 100% »ýü È°¼ºÇü ¼Ò¿° ÁøÅëÁ¦ ÀÔ´Ï´Ù.
ÀûÀÀÁõ
1.±Þ¼º ¹× ¸¸¼º °üÀý¿° : ¸¸¼º ´Ù¹ß¼º °üÀý¿°, ·ù¸¶Æ¼½º¼º °üÀý¿° µî
2.°üÀýÁõ
3.¿°Áõ¼º ·ù¸¶Æ¼½º Áúȯ: °­Á÷¼ºÃ´Ãß¿°, ±ÙÀ°·ù¸¶Æ¼Áò 4.¿°Áõ, ÅëÁõ ¹× ¹ß¿­À» ¼ö¹ÝÇÏ´Â °¨¿°ÁõÀÇ Ä¡·á º¸Á¶
°ü·ÃƯÇã
1.J Clin Pharmacol 36;7S-15S, 1996 J Clin Pharmacol 36;88-94S, 1996
2. J Clin Pharmacol 36;3S-6S, 1996

½Ã³×Ãò¶ó½Ã·´

°³¿ä
1. ¼­¾çÀÇ ¾ÆÀ̺ñ¿±°ú µ¿¾çÀÇ È²·Ã Á¶ÇÕÀ¸·Î ÃÖ»óÀÇ È°¼º½Ã³ÊÁö¸¦ º¸ÀÌ´Â ÁøÇØ°Å´ãÁ¦ °³¹ß. ¾È±¹¾àÇ°¢ß ÀÚü°³¹ßÇÑ ¾ÈÀüÇÏ°í ¿ì¼öÇÑ ÁøÇØ, °Å´ã ¹× Ç׿° È°¼º¹°À» °¡Áø õ¿¬¹°½Å¾à 5È£
ÀûÀÀÁõ
1. ±Þ¼º »ó±âµµ °¨¿°, ¸¸¼º ¿°Áõ¼º ±â°üÁö¿°
¼ö»ó±â·Ï
1. 2011³â Áö½Ä°æÁ¦ºÎ ±Û·Î¹ú ¼±µµ õ¿¬¹°½Å¾à °³¹ß »ç¾÷ ¼±Á¤
R&D PRODUCT

·çÆÄÇÉÁ¤ (Ç×È÷½ºÅ¸¹Î ½Å¾à)

°³¿ä
1. Ç×È÷½ºÅ¸¹Î È¿°ú¿Í Ç÷¼ÒÆÇ È°¼ºÀÎÀÚ(Platelet Activating Factor, PAF)¸¦ ¾ïÁ¦ÇÏ´Â ÀÌÁß ÀÛ¿ë(Daual action)
2. ¾àÈ¿ ¹ßÇö½Ã°£ÀÌ ºü¸£¸ç, ±¤¹üÀ§ÇÏ°í °­·ÂÇÑ ¾Ë·¹¸£±â ¹ÝÀÀ ¾ïÁ¦ ¹× Ç׿°Áõ È¿°ú
3. Ç×È÷½ºÅ¸¹ÎÁ¦ ÃÖÃÊ·Î 1³â°£ÀÇ Àå±â ¾ÈÁ¤¼º ÀÔÁõ
ÀûÀÀÁõ
¾Ë·¹¸£±â¼º ºñ¿° ¹× µÎµå·¯±â Áõ»ó Ä¡·á
°ü·Ã³í¹®
1. Mullol J, et al, Allergy, 2015.
2. Barron et al, Methods Find, Clin, Pharmacol, 2005;27(Suppl.2):161.
3. Rarris et al, Allergy, 2000;55(63):94-95.
4. Stuebner P, et al, Ann Allergy Asthma lmmunol, 2006 Jan;96(1):37-44.
5. Maiti R, et al, Arch Otolaryngol Head Neck Sung, 2010 Aug;136(8):796-800.
6. Maiti R, et al, J Durgs Dematol, 2011 Dec;10(12):1444-50.
7. Valero A, et al, Drugs Saf, 2009:32(1):33-42.
Á¦ÈÞ»ç
Uriach(½ºÆäÀÎ) : 2003³â Ãâ½Ã ÈÄ Àü¼¼°è 70¿©°³±¹¿¡¼­ ÆǸŠÁß

ºñ³ë½ºÅä ¹ßÆ÷Á¤

°³¿ä
1. ¹°¿¡ ³ì¿© ¸¶½Ã´Â ¹ßÆ÷Á¤ ÇüÅÂÀÇ °ñ´Ù°øÁõ Ä¡·áÁ¦ÀÔ´Ï´Ù.
2. ±âÁ¸ Á¤Á¦º¸´Ù º¹¾à ÆíÀǼºÀÌ Å©°í À§Àå°ü ÀÚ±ØÀÌ Àû½À´Ï´Ù.
ÀûÀÀÁõ
Æó°æÈÄ ¿©¼ºÀÇ °ñ´Ù°øÁõ Ä¡·á, ³²¼ºÀÇ °ñ´Ù°øÁõ Ä¡·á
Á¦ÈÞ»ç
EffRx(½ºÀ§½º) : ¹Ì±¹ FDA. À¯·´ EMA Çã°¡

Æú¶ô½º

°³¿ä
½Å°³³ä ¼ºÀÎ º¯ºñ Áõ»ó Ä¡·áÁ¦
ÀûÀÀÁõ
¼ºÀÎÀÇ º¯ºñ Áõ»ó Ä¡·á
Á¦ÈÞ»ç
Beaufor lpsen(ÇÁ¶û½º) : ÇÁ¶û½º º¯ºñ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À² 1À§(2003³â)